According to the NKL-code scheme, the suppression of MSX1 is a prerequisite for the progression of normal B-cell differentiation, and reduced MSX1 expression in BCP-ALL patients is correlated with aberrantly expressed MEIS1 (Figure S3), supporting the clinical applicability of our findings. The gene discussed is MEIS1; the disease is acute lymphoblastic leukemia.